September 14, 2025 — The attention economy has been getting a lot of, well, attention lately. In fact, the phenomenon is nothing new. People have been competing for the attention of Americans since the rise of cheap daily newspapers in the 19th century. But lately it seems that the quest to command attention is taking over more and more […]
September 6, 2025 — The short supply, high prices, and despicable insurance restrictions for advanced obesity medicines have created many problems. For example, compounding of these medicines has been and continues to be controversial – for good reasons. Now, FDA is recognizing one of the most pernicious threats to emerge from this situation – sketchy sellers of “research” peptides. […]
August 10, 2025 — Sisyphus, the myth of a person condemned to a futile task of rolling a boulder uphill for eternity, has long been an apt metaphor for obesity medicine. He still is, said Donna Ryan yesterday at the Louisiana 2025 Obesity Conference in New Orleans. But the narrative has shifted dramatically, she explained. Before this shift, the […]
August 7, 2025 — At the opening of the ANZMOSS (Australian and New Zealand Metabolic and Obesity Surgery Society) meeting today, we had the unique privilege of helping people peer into the future of obesity care. Endocrine surgeon Juan Pablo Pantoja presented a view of the future of bariatric surgery in the era of a medical frenzy. The frenzy, […]
July 15, 2025 — At ENDO2025 Saturday, we got a fresh view of the future that lies ahead for medical and surgical obesity care. In a sharp contrast to either/or constructs that pit medical and surgical care as rivals, endocrinology fellow Angela Rao presented data pointing to complementary roles for medical and surgical obesity care. Analyzing data from 846 […]
July 1, 2025 — A dramatic race is progressing quietly and out of view for most of us. It is the race toward better therapy for the liver disease doctors know as MASH (metabolic associated steatohepatitis), which has close ties to obesity. And likewise because of advances in obesity science, progress in treating MASH is advancing with blinding speed […]
June 24, 2025 — On the closing day of the ADA Scientific Sessions in Chicago, we got a good look at two remarkable new obesity drugs. Both of them have potential to bring important advances. Both of them need more work before they will be ready to go to FDA for approval. This was a rare treat. Bimagrumab The […]
June 17, 2025 — While much of the public has focused on the remarkable effects of GLP-1 agonists for many people living with obesity, an even more remarkable story has largely escaped notice. In March, FDA approved the first ever treatment for Prader-Willi syndrome. This drug, an extended-release form of diazoxide choline, is transforming the lives of families of […]
June 14, 2025 — As the upcoming Scientific Sessions for the American Diabetes Association draws closer, the drumbeat for amycretin as a promising new therapy for obesity is growing louder. At the meeting, Novo Nordisk plans to present two different studies to strengthen the case for this novel dual agonist. It targets both GLP-1 and amylin receptors. Then yesterday […]
June 13, 2025 — Thoughtful reporting by Jackie Snow in the New York Times prompts us to wonder about the possibility of a “contagion effect” from GLP-1s in families. When a parent receives highly effective treatment for obesity, what might the effect be on other family members? Of course, any answers to this question come from anecdotal observations. They […]
